|
|
|
|
|
|
|
|
|
|
HealthLinx (ASX: HTX) has reported that UK distribution partner Intus Healthcare is targeting a significant share of the potential 750,000 annual ovarian cancer diagnostic tests undertaken in the UK with the product launch of OvPlex™ on 25 February 2010.
The company obtained European Certification for OvPlex™ paving the way to market and sell the product within the European community.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.